These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10227779)

  • 1. Specific immunoadsorbent for myasthenia gravis treatment: development of synthetic peptide designed to remove antiacetylcholine receptor antibody.
    Miyahara T; Oka K; Nakaji S
    Ther Apher; 1998 Aug; 2(3):246-8. PubMed ID: 10227779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adsorption column for myasthenia gravis treatment: Medisorba MG-50.
    Nakaji S; Hayashi N
    Ther Apher Dial; 2003 Feb; 7(1):78-84. PubMed ID: 12921120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective removal of anti-acetylcholine receptor antibodies and IgG in vitro with an immunoadsorbent containing immobilized sulfathiazole.
    Yamamoto Y; Sameshima T; Akaike T
    Artif Organs; 1990 Oct; 14(5):334-41. PubMed ID: 2241600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.
    Takamori M; Ide Y
    Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia gravis therapy: immunoadsorbent may eliminate need for plasma products.
    Sawada K; Malchesky PS; Koo AP; Mitsumoto H
    Cleve Clin J Med; 1993; 60(1):60-4. PubMed ID: 8443936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum.
    Guo CY; Li ZY; Xu MQ; Yuan JM
    J Immunol Methods; 2005 Aug; 303(1-2):142-7. PubMed ID: 16040047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor.
    Morell SW; Trinh VB; Gudipati E; Friend A; Page NA; Agius MA; Richman DP; Fairclough RH
    Mol Immunol; 2014 Mar; 58(1):116-31. PubMed ID: 24333757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myasthenogenic significance of synthetic alpha-subunit peptide 183-200 of Torpedo californica and human acetylcholine receptor.
    Takamori M; Okumura S; Nagata M; Yoshikawa H
    J Neurol Sci; 1988 Jun; 85(2):121-9. PubMed ID: 3260271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
    Takamori M; Maruta T
    Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.
    Sun C; Meng F; Li Y; Jin Q; Li H; Li F
    Artif Cells Blood Substit Immobil Biotechnol; 2010 Apr; 38(2):99-102. PubMed ID: 20196680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis.
    Zhang GX; Shi FD; Zhu J; Xiao BG; Levi M; Wahren B; Yu LY; Link H
    J Neuroimmunol; 1998 May; 85(1):96-101. PubMed ID: 9627002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immusorba TR and Immusorba PH: basics of design and features of functions.
    Yoshida M; Tamura Y; Yamada Y; Yamawaki N; Yamashita Y
    Ther Apher; 1998 Aug; 2(3):185-92. PubMed ID: 10227768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor.
    Shenoy M; Oshima M; Atassi MZ; Christadoss P
    Clin Immunol Immunopathol; 1993 Mar; 66(3):230-8. PubMed ID: 7679342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
    Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
    Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S; LeBoeuf RD; Blalock JE
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass.
    Whiting PJ; Vincent A; Newsom-Davis J
    J Neuroimmunol; 1983 Aug; 5(1):1-9. PubMed ID: 6874919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid immunoadsorbent radioimmunoassay for anti-acetylcholine receptor antibody.
    Tindall RS; Kent M; Wells L
    J Immunol Methods; 1981; 45(1):1-14. PubMed ID: 7288190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation in myasthenia gravis plasma by Torpedo acetylcholine receptor liposomes.
    DuPont BL; Koethe SM; McQuillen MP
    Immunol Invest; 1985 Oct; 14(5):415-20. PubMed ID: 4077155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunopathology of myasthenia gravis.
    Lennon VA
    Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis.
    Lennon VA; Griesmann GE
    Neurology; 1989 Aug; 39(8):1069-76. PubMed ID: 2474772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.